{"id":"NCT01572727","sponsor":"Novartis Pharmaceuticals","briefTitle":"A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation","officialTitle":"A Randomized, Double-blind, Placebo Controlled, Phase II/III Study of BKM120 Plus Paclitaxel in Patients With HER2 Negative Inoperable Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Pathway Activation.","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2012-08","primaryCompletion":"2015-06","completion":"2015-06","firstPosted":"2012-04-06","resultsPosted":"2017-01-27","lastUpdate":"2017-03-09"},"enrollment":416,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"Paclitaxel","otherNames":["Taxol"]},{"type":"DRUG","name":"BKM120 matching placebo","otherNames":[]},{"type":"DRUG","name":"BKM120","otherNames":["Buparlisib"]}],"arms":[{"label":"BKM120 and paclitaxel","type":"EXPERIMENTAL"},{"label":"Placebo and paclitaxel","type":"ACTIVE_COMPARATOR"}],"summary":"This study evaluated whether the addition of daily BKM120 to weekly paclitaxel was effective and safe in treating patients with HER2- locally advanced or metastatic breast cancer.","primaryOutcome":{"measure":"Progression-free Survival (PFS)Assessed by Local Investigator's Assessment (Phase ll)","timeFrame":"Every 8 weeks from randomization until disease progression up to 10 months after futility was analyzed","effectByArm":[{"arm":"BKM120 and Paclitaxel","deltaMin":8,"sd":null},{"arm":"Placebo and Paclitaxel","deltaMin":9.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":11},"locations":{"siteCount":112,"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","Czechia","France","Germany","Hong Kong","Hungary","Israel","Italy","Japan","Netherlands","Russia","Singapore","South Africa","South Korea","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":61,"n":202},"commonTop":["ALOPECIA","DIARRHOEA","NAUSEA","FATIGUE","RASH"]}}